TACTILE SYSTEMS TECHNOLOGY Investors With Losses Greater Than $100,000 …

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

PHILADELPHIA, Oct. 12, 2020 (GLOBE NEWSWIRE) — Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of Tactile Systems Technology, Inc. (“Tactile” or the “Company”) ( NASDAQ: TCMD ) to determine whether Tactile engaged in securities fraud or other unlawful business practices.

Tactile investors who purchased, or otherwise acquired, the Company’s securities between May 7, 2018 and June 8, 2020, both dates inclusive (the “Class Period”), and suffered losses greater than $100,000 are encouraged to complete Kehoe Law Firm’s Securities Class Action Questionnaire or contact Michael Yarnoff, Esq., (215) 792-6676, Ext. 804, [email protected], [email protected], to discuss the securities investigation or potential legal claims.

IF YOU WISH TO SERVE AS LEAD PLAINTIFF, YOU MUST MOVE THE COURT NO LATER THAN NOVEMBER 30, 2020. To be

Read More
Read More

Bernstein Liebhard is Investigating Tactile Systems Technology, Inc. For Violations of the Securities Laws

Bernstein Liebhard, a nationally acclaimed investor rights law firm, is investigating potential securities fraud claims on behalf of shareholders of Tactile Systems Technology, Inc. (“Tactile” or the “Company”) (NASDAQ: TCMD) resulting from allegations that Tactile might have issued misleading information to the investing public.

If you purchased Tactile securities, and/or would like to discuss your legal rights and options please visit TCMD Shareholder Investigation or contact Matthew E. Guarnero toll free at (877) 779-1414 or [email protected]

On June 8, 2020, research firm OSS Research published a scathing report about the Company entitled “Strong Sell on Tactile Systems: Bloated Stock Needs Compression Therapy.” In the report, OSS Research accused Tactile of (1) overstating its total addressable market by nearly $4.7 billion, (2) using a “‘daisy-chaining kick-back scheme’ that has resulted in rampant overprescribing and rapid market share gains at the expense of patients, insurers and the public,” and (3) concealing Medicare

Read More
Read More